103 related articles for article (PubMed ID: 7990857)
1. Parkinson's disease and milacemide.
Youdim MB
Mov Disord; 1994 Sep; 9(5):585-6. PubMed ID: 7990857
[No Abstract] [Full Text] [Related]
2. Milacemide therapy for Parkinson's disease.
Giuffra ME; Sethy VH; Davis TL; Mouradian MM; Chase TN
Mov Disord; 1993; 8(1):47-50. PubMed ID: 8380487
[TBL] [Abstract][Full Text] [Related]
3. MAO-B inhibitors in Parkinson's disease.
Olanow CW
Adv Neurol; 1993; 60():666-71. PubMed ID: 8420207
[No Abstract] [Full Text] [Related]
4. N-methyl-D-aspartate (NMDA) antagonist and Parkinson's disease: a pilot study with dextromethorphan.
Montastruc JL; Fabre N; Rascol O; Senard JM; Blin O
Mov Disord; 1994 Mar; 9(2):242-3. PubMed ID: 8196695
[No Abstract] [Full Text] [Related]
5. An open multicenter study of the efficacy of MDL 72,974A, a monoamine oxidase type B (MAO-B) inhibitor, in Parkinson's disease.
Myllylä VV; Sotaniemi KA; Aasly J; Sjaastad O; Rinne U; McIntyre T; Cremer G
Adv Neurol; 1993; 60():676-80. PubMed ID: 8420209
[No Abstract] [Full Text] [Related]
6. Is the decreasing responsiveness of axial motor symptoms to L-dopa in elderly parkinsonian patients related to age-associated nonparkinsonian pathologies?
Ransmayr G; Künig G; Neubauer M; Wagner M; Bösch S; Kreczy-Kleedorfer B
Adv Neurol; 1993; 60():685-9. PubMed ID: 8420211
[No Abstract] [Full Text] [Related]
7. Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what.
Metman LV; Konitsiotis S; Chase TN
Mov Disord; 2000 Jan; 15(1):3-8. PubMed ID: 10634235
[No Abstract] [Full Text] [Related]
8. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
9. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
Parkinson Study Group
Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
[TBL] [Abstract][Full Text] [Related]
10. Striatal dopaminoceptive system changes and motor response complications in L-dopa-treated patients with advanced Parkinson's disease.
Chase TN; Engber TM; Mouradian MM
Adv Neurol; 1993; 60():181-5. PubMed ID: 8420133
[No Abstract] [Full Text] [Related]
11. Physiological mechanisms and assessment of motor disorders in Parkinson's disease.
Steg G; Johnels B
Adv Neurol; 1993; 60():358-65. PubMed ID: 8420153
[No Abstract] [Full Text] [Related]
12. Parkinson's disease. The L-dopa era.
Yahr MD
Adv Neurol; 1993; 60():11-7. PubMed ID: 8420128
[No Abstract] [Full Text] [Related]
13. "Ottorino Rossi" Award 2000. New targets for therapy in Parkinson's disease: pathogenesis and pathophysiology.
Greenamyre JT
Funct Neurol; 2000; 15(2):67-80. PubMed ID: 10916718
[No Abstract] [Full Text] [Related]
14. Rasagiline. Parkinson's disease: a simple me-too.
Prescrire Int; 2006 Dec; 15(86):220. PubMed ID: 17167927
[TBL] [Abstract][Full Text] [Related]
15. Research diagnostic criteria for Parkinson's disease.
Ward CD; Gibb WR
Adv Neurol; 1990; 53():245-9. PubMed ID: 2239463
[No Abstract] [Full Text] [Related]
16. Single-dose L-dopa response in early Parkinson's disease: measurements with optoelectronic recording technique.
Johnels B; Ingvarsson PE; Holmberg B; Matousek M; Steg G
Mov Disord; 1993; 8(1):56-62. PubMed ID: 8419808
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
Henchcliffe C; Schumacher HC; Burgut FT
Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
[TBL] [Abstract][Full Text] [Related]
18. Rasagiline in Parkinson's disease.
Schwarzschild MA
N Engl J Med; 2010 Feb; 362(7):658; author reply 658-9. PubMed ID: 20187261
[No Abstract] [Full Text] [Related]
19. Renaissance of amantadine in the treatment of Parkinson's disease.
Blanchet PJ; Metman LV; Chase TN
Adv Neurol; 2003; 91():251-7. PubMed ID: 12442683
[No Abstract] [Full Text] [Related]
20. Striatal molecular mechanisms and motor dysfunction in Parkinson's disease.
Chase TN; Konitsiotis S; Oh JD
Adv Neurol; 2001; 86():355-60. PubMed ID: 11553996
[No Abstract] [Full Text] [Related]
[Next] [New Search]
